Alison Jane Williamson

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.